ЛЕЧЕНИЕ БОЛЕВОГО СИНДРОМА НА АМБУЛАТОРНО-ПОЛИКЛИНИЧЕСКОМ ЭТАПЕ. ВЫБОР АНАЛЬГЕТИКА С ПОЗИЦИЙ КОМОРБИДНОСТИ И ЛЕКАРСТВЕННОЙ БЕЗОПАСНОСТИ В ФОКУСЕ – ДЕКСКЕТОПРОФЕН

Pain is one of the most common symptoms in modern clinical practice and one of the most common reasons why patients seek medical care at an outpatient clinic. Traditionally, nonsteroidal anti-inflammatory drugs (NSAIDs) are the leading means of protecting peripheral pain receptors. However, with the intake of NSAIDs, a whole range of different complications is associated. Comorbidity and drug safety are closely related to the use of NSAIDs. In the presented review, domestic and foreign studies of dexketoprofen for the treatment of pain syndrome in the outpatient and polyclinic stage were analyzed. The emergence of the domestic brand-generic dexketoprofen, the drug Flamadex®, in the Russian pharmaceutical market increases the availability of effective and safe therapy of pain syndrome in patients with comorbid pathology at the outpatient and polyclinic stage.